These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

544 related articles for article (PubMed ID: 10705309)

  • 1. Interferon-gamma and its functional receptors overexpression in benign prostatic hyperplasia and prostatic carcinoma: parallelism with c-myc and p53 expression.
    Royuela M; de Miguel MP; Ruiz A; Fraile B; Arenas MI; Romo E; Paniagua R
    Eur Cytokine Netw; 2000 Mar; 11(1):119-27. PubMed ID: 10705309
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunohistochemical comparative analysis of transforming growth factor alpha, epidermal growth factor, and epidermal growth factor receptor in normal, hyperplastic and neoplastic human prostates.
    De Miguel P; Royuela ; Bethencourt R; Ruiz A; Fraile B; Paniagua R
    Cytokine; 1999 Sep; 11(9):722-7. PubMed ID: 10479409
    [TBL] [Abstract][Full Text] [Related]  

  • 3. INSL3 in the benign hyperplastic and neoplastic human prostate gland.
    Klonisch T; Müller-Huesmann H; Riedel M; Kehlen A; Bialek J; Radestock Y; Holzhausen HJ; Steger K; Ludwig M; Weidner W; Hoang-Vu C; Hombach-Klonisch S
    Int J Oncol; 2005 Aug; 27(2):307-15. PubMed ID: 16010410
    [TBL] [Abstract][Full Text] [Related]  

  • 4. c-met proto-oncogene expression in benign and malignant human prostate tissues.
    Pisters LL; Troncoso P; Zhau HE; Li W; von Eschenbach AC; Chung LW
    J Urol; 1995 Jul; 154(1):293-8. PubMed ID: 7539865
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Apoptosis-related gene expression in benign prostatic hyperplasia and prostate carcinoma.
    Iacopino F; Angelucci C; Lama G; Zelano G; La Torre G; D'Addessi A; Giovannini C; Bertaccini A; Macaluso MP; Martorana G; Sica G
    Anticancer Res; 2006; 26(3A):1849-54. PubMed ID: 16827116
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of canine basal cells in prostatic post natal development, induction of hyperplasia, sex hormone-stimulated growth; and the ductal origin of carcinoma.
    Leav I; Schelling KH; Adams JY; Merk FB; Alroy J
    Prostate; 2001 May; 47(3):149-63. PubMed ID: 11351344
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunohistochemical analysis of the IL-6 family of cytokines and their receptors in benign, hyperplasic, and malignant human prostate.
    Royuela M; Ricote M; Parsons MS; García-Tuñón I; Paniagua R; de Miguel MP
    J Pathol; 2004 Jan; 202(1):41-9. PubMed ID: 14694520
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of canine basal cells in postnatal prostatic development, induction of hyperplasia, and sex hormone-stimulated growth; and the ductal origin of carcinoma.
    Leav I; Schelling KH; Adams JY; Merk FB; Alroy J
    Prostate; 2001 Aug; 48(3):210-24. PubMed ID: 11494337
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of peroxisome proliferator-activated receptor (PPAR) in human prostate cancer.
    Segawa Y; Yoshimura R; Hase T; Nakatani T; Wada S; Kawahito Y; Kishimoto T; Sano H
    Prostate; 2002 May; 51(2):108-16. PubMed ID: 11948965
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression and function of pro-inflammatory interleukin IL-17 and IL-17 receptor in normal, benign hyperplastic, and malignant prostate.
    Steiner GE; Newman ME; Paikl D; Stix U; Memaran-Dagda N; Lee C; Marberger MJ
    Prostate; 2003 Aug; 56(3):171-82. PubMed ID: 12772186
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased expression of lymphocyte-derived cytokines in benign hyperplastic prostate tissue, identification of the producing cell types, and effect of differentially expressed cytokines on stromal cell proliferation.
    Kramer G; Steiner GE; Handisurya A; Stix U; Haitel A; Knerer B; Gessl A; Lee C; Marberger M
    Prostate; 2002 Jun; 52(1):43-58. PubMed ID: 11992619
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Unopposed c-MYC expression in benign prostatic epithelium causes a cancer phenotype.
    Williams K; Fernandez S; Stien X; Ishii K; Love HD; Lau YF; Roberts RL; Hayward SW
    Prostate; 2005 Jun; 63(4):369-84. PubMed ID: 15937962
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunohistochemical expression of retinoblastoma and p53 tumor suppressor genes in prostatic intraepithelial neoplasia: comparison with prostatic adenocarcinoma and benign prostate.
    Tamboli P; Amin MB; Xu HJ; Linden MD
    Mod Pathol; 1998 Mar; 11(3):247-52. PubMed ID: 9521470
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FGF17 is an autocrine prostatic epithelial growth factor and is upregulated in benign prostatic hyperplasia.
    Polnaszek N; Kwabi-Addo B; Wang J; Ittmann M
    Prostate; 2004 Jun; 60(1):18-24. PubMed ID: 15129425
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of c-jun oncogene in hyperplastic and carcinomatous human prostate.
    Tiniakos DG; Mitropoulos D; Kyroudi-Voulgari A; Soura K; Kittas C
    Urology; 2006 Jan; 67(1):204-8. PubMed ID: 16413376
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Caspase 3 expression in benign prostatic hyperplasia and prostate carcinoma.
    O'Neill AJ; Boran SA; O'Keane C; Coffey RN; Hegarty NJ; Hegarty P; Gaffney EF; Fitzpatrick JM; Watson RW
    Prostate; 2001 May; 47(3):183-8. PubMed ID: 11351347
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epidermal growth factor modulates the expression of vascular endothelial growth factor in the human prostate.
    Ravindranath N; Wion D; Brachet P; Djakiew D
    J Androl; 2001; 22(3):432-43. PubMed ID: 11330643
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 5alpha-reductase type 1 immunostaining is enhanced in some prostate cancers compared with benign prostatic hyperplasia epithelium.
    Thomas LN; Douglas RC; Vessey JP; Gupta R; Fontaine D; Norman RW; Thompson IM; Troyer DA; Rittmaster RS; Lazier CB
    J Urol; 2003 Nov; 170(5):2019-25. PubMed ID: 14532845
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ki-67 antigen and P53 protein expression in benign and malignant prostatic lesions. Immunohistochemical quantitative study.
    Sasor A; Wagrowska-Danilewicz M; Danilewicz M
    Pol J Pathol; 2000; 51(1):31-6. PubMed ID: 10833901
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Down-regulation of neu/HER-2 by interferon-gamma in prostate cancer cells.
    Kominsky SL; Hobeika AC; Lake FA; Torres BA; Johnson HM
    Cancer Res; 2000 Jul; 60(14):3904-8. PubMed ID: 10919667
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.